MedicalSystem Biotechnology Co Ltd
MedicalSystem Biotechnology Co Ltd operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution, generating revenue primarily through the sale and provision of medical technologies and related services.
Business. MedicalSystem Biotechnology Co Ltd (300439.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MedicalSystem Biotechnology Co Ltd (300439.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
MedicalSystem Biotechnology Co Ltd maintains a strong liquidity position, with a market capitalization of 3.54 billion CNY and an enterprise value to revenue ratio of 2.34, indicating a relatively low valuation compared to its revenue base. The company's debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. However, the risk assessment notes a medium liquidity risk, with net cash being negative after subtracting total debt, which could signal potential short-term liquidity constraints.
In terms of profitability, the company reported a revenue of 1.54 billion CNY, with a total equity of 2.95 billion CNY, indicating a solid equity base. The operating cash flow of 266.61 million CNY supports ongoing operations and reinvestment. While the company's profitability metrics are not explicitly provided, the low debt-to-equity ratio and positive operating cash flow suggest a stable financial performance relative to industry norms.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn.
The company's growth trajectory is supported by a reported revenue of 1.54 billion CNY, with analyst estimates suggesting a potential increase to 3.14 billion CNY. This indicates a significant growth opportunity, although the company's capital expenditure of -191.41 million CNY suggests a focus on cost management and operational efficiency.
The risk assessment highlights a low dilution risk, with no immediate pressure for equity issuance. However, the company's liquidity risk remains a concern due to the negative net cash position after accounting for total debt. The absence of detailed risk factors in the input data limits a more comprehensive evaluation of potential dilution sources.
Recent events, including the latest financial filings and transcripts, are not detailed in the input data, which restricts the ability to provide a more nuanced analysis of the company's recent performance and strategic direction.
- MedicalSystem Biotechnology Co Ltd has a conservative capital structure with a low debt-to-equity ratio of 0.02.
- The company's enterprise value to revenue ratio of 2.34 suggests it is undervalued relative to its revenue.
- The company's liquidity risk is medium, with a negative net cash position after subtracting total debt.
- Analyst estimates indicate a potential revenue increase to 3.14 billion CNY, suggesting strong growth prospects.
- The company's revenue is concentrated in a single business segment, which could pose a risk if the primary market experiences a downturn.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- MedicalSystem Biotechnology Co Ltd Market data — financials · 2026-05-26
- MedicalSystem Biotechnology Co Ltd Market data — analyst estimates · 2026-05-26